Pfizer’s Maternal RSV Vaccine Quest May Hinge On FDA Advisors’ Views of Preterm Birth Data

17 May 2023

A numerical – but not statistically significant – imbalance in preterm births was seen in two Pfizer studies of its RSV vaccine when given to pregnant people with the aim of protecting newborns.

mom and infant — FDA’s advisors will vote 18 May on Pfizer’s maternal RSV vaccine program to protect infants • Source: Shutterstock

Pfizer’s Maternal RSV Vaccine Quest May Hinge On FDA Advisors’ Views of Preterm Birth Data

More from US FDA Performance Tracker

More from Regulatory Trackers